Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
Oculis reported new biomarker data from the Phase 2 ACUITY trial showing Privosegtor reduced post-onset increases in plasma NfL and GFAP versus placebo in optic neuritis patients. The biomarker findings corroborate previously reported functional results, including +18-letter low-contrast visual acuity gains at Month 3 and preserved retinal structure.
Key figures
- Drug Name
- Privosegtor
- Phase Of Trial
- Phase 2
- Lsvc letter gain
- +18-letter gains in low-contrast visual acuity at Month 3 vs steroid alone
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.